Evidence map›Paper›PMID 34950381›Full record

ArticleThe Neurohospitalist2022

Treating High-Risk TIA and Minor Stroke Patients With Dual Antiplatelet Therapy: A National Survey of Emergency Medicine Physicians.

Ava L Liberman, Andrea R Lendaris, Natalie T Cheng, Nicole L Kaban, Sara K Rostanski, Charles Esenwa, Benjamin R Kummer, Daniel L Labovitz, Shyam Prabhakaran, Benjamin W Friedman

Open access · bronzeAbstract read
In one paragraph

Article in The Neurohospitalist, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Ava L LibermanDepartment of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID https://orcid.org/0000-0003-0184-6035
Andrea R LendarisDepartment of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Natalie T ChengDepartment of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Nicole L KabanDepartment of Medicine, Section of Emergency Medicine, Louisiana State University, New Orleans, LA, USA.
Sara K RostanskiDepartment of Neurology, New York University School of Medicine, NY, USA.
Charles EsenwaDepartment of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Benjamin R KummerDepartment of Neurology, Icahn School of Medicine at Mount Sinai, NY, USA.
Daniel L LabovitzDepartment of Neurology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Shyam PrabhakaranDepartment of Neurology, University of Chicago, Chicago, IL, USA.
Benjamin W FriedmanDepartment of Emergency Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
Albert Einstein College of Medicine · USIcahn School of Medicine at Mount Sinai · USLouisiana State University · USNew York University · USUniversity of Chicago · US

Funding

CTSA Administrative Supplement for Informatics Core: A novel AI/ML system to predict respiratory failure and ARDS in Covid-19 patientsUL1TR002556 · NCATS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI KELLER, MARLA J, KIM, MIMI Y · 2018 to 2022
$26.7M
Targeted Healthcare Engineering for Systems Interventions in Stroke (THESIS)R18HS027264 · AHRQ · UNIVERSITY OF CHICAGO · PI HOLL, JANE LOUISE, PRABHAKARAN, SHYAM · 2019 to 2022
$2.5M
Enhancing Stroke Prehospital and Emergency Evaluation and Delivery (E-SPEED)R18HS025359 · AHRQ · UNIVERSITY OF CHICAGO · PI PRABHAKARAN, SHYAM · 2018 to 2021
$1.5M
MOLECULAR GENETICS OF ZEBRAFISH PIGMENT CELL DEVELOPMENTF32NS010764 · NINDS · UNIVERSITY OF WASHINGTON · PI LISTER, JAMES A · 1998 to 2001
$73k
AHRQ HHS R18 HS025359AHRQ HHS R18 HS027264NCATS NIH HHS UL1 TR002556NINDS NIH HHS F32 NS010764
6 · The paper itself

Abstract

backgroundTreatment with aspirin plus clopidogrel, dual antiplatelet therapy (DAPT), within 24 hours of high-risk transient ischemic attack (TIA) or minor stroke symptoms to eligible patients is recommended by national guidelines. Whether or not this treatment has been adopted by emergency medicine (EM) physicians is uncertain.

methodsWe conducted an online survey of EM physicians in the United States. The survey consisted of 13 multiple choice questions regarding physician characteristics, practice settings, and usual approach to TIA and minor stroke treatment. We report participant characteristics and use chi-squared tests to compare between groups.

resultsWe included 162 participants in the final study analysis. 103 participants (64%) were in practice for >5 years and 96 (59%) were at nonacademic centers; all were EM board-certified or board-eligible. Only 9 (6%) participants reported that they would start DAPT for minor stroke and 8 (5%) reported that they would start DAPT after high-risk TIA. Aspirin alone was the selected treatment by 81 (50%) participants for minor stroke patients who presented within 24 hours of symptom onset and were not candidates for thrombolysis. For minor stroke, 69 (43%) participants indicated that they would defer medical management to consultants or another team. Similarly, 75 (46%) of participants chose aspirin alone to treat high-risk TIA; 74 (46%) reported they would defer medical management after TIA to consultants or another team.

conclusionIn a survey of EM physicians, we found that the reported rate of DAPT treatment for eligible patients with high-risk TIA and minor stroke was low.

Indexed as

acute ischemic strokeminor strokesurveytransient ischemic attack

Identifiers

PMID34950381
PMCPMC8689540
OpenAlexW3169598858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.